Central Serous Retinopathy risk factors and efficacy of Dorzolamid drop
Phase 2
- Conditions
- Central Serous Retinopathy.Central serous chorioretinopathyH35.71
- Registration Number
- IRCT20180703040323N1
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
All patients that come to ophtalmology clinic of Valiasr hospital that have definite diagnose of Central Serous Retinopathy with imaging
Exclusion Criteria
Every kind of other Retinopathies
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual Acuity and OCT. Timepoint: Three weeks. Method of measurement: Snellen chart and OCT.
- Secondary Outcome Measures
Name Time Method